

A CE PRE-CONFERENCE IN CONJUNCTION WITH THE CONSORTIUM OF MULTIPLE SCLEROSIS CENTERS

VIRTUAL
OPTION
AVAILABLE

AN UPDATE ON MULTIPLE SCLEROSIS PATIENT CARE FOR ADVANCED PRACTICE PROVIDERS

Tuesday, May 27, 2025 • 4-6pm Mountain Standard Time
Sheraton Phoenix Downtown
Valley of The Sun Ballroom D, Second Level
340 North 3rd Street • Phoenix, AZ 85004

Advanced Curriculum
for Multiple Sclerosis

Earn 2.0 CE Credits

CHAIR



Amy Perrin Ross, APN,
MSN, CNRN, MSCN

FACULTY



Lisa Marie
Fox, PA-C



Sarah Morrow, MD,
MS, FRCPC, FAAN



Scott D.
Newsome, DO



Jiwon Oh,
MD, PhD, FRCPC



Claire S.
Riley, MD

AGENDA

4:00 pm – 4:45 pm MST: Diagnostic Update –
Sarah Morrow, MD, MS and Jiwon Oh, MD

- a. McDonald Criteria 2024
 - i. The Importance of Early Diagnosis and Intervention
 - ii. Differential Diagnosis and MS Mimics
 - iii. Biomarkers for Diagnosis and Monitoring Disease Progression
 1. CMSC MRI Guidelines
 - a. Central Vein Sign
 - b. Paramagnetic Rim Lesion
 - iv. Emerging Biomarkers
 1. NFL and Kappa Light Chains
 2. Other Biomarkers

4:45 pm – 5:30 pm MST: Review of Current and Emerging Disease
Modifying Therapies and Mitigating Their Adverse Events –
Scott D. Newsome, DO and Lisa Marie Fox, PA-C

- a. Current Therapies
 - i. High Efficacy vs. Low to Moderate Efficacy DMTs
 - ii. Side Effects and Management
 - iii. Rationale for Treatment Initiation Choice and Treatment Switch
- b. Update on BTK Therapeutics

5:30 pm – 6:00 pm MST: The Evolving Role of CAR T Therapeutics
in the Management of MS Neuroinflammation – *Claire S. Riley, MD*

- a. Mechanism of Action and Potential Role of CAR T-cell Therapy
in Managing Neuroinflammation in Patients with MS
- b. Clinical Trial Data for CAR T-cell Therapeutics in Neurology
- c. Applications of CAR T-cell Therapy in Oncology and the
Transition from Oncology to Neurology

**Supported by an educational grant from Bristol Myers Squibb*

LEARNING OBJECTIVES

1. Review the updated methods for MS diagnostics including the 2024 McDonald Criteria, biomarkers, and imaging techniques
2. Evaluate the advances in the mechanisms of action, clinical trial data, and adverse events for disease modifying therapies for patients with multiple sclerosis
3. Review the mechanism of action and potential role of CAR T-cell therapy in managing neuroinflammation in patients with MS

JOINT ACCREDITATION STANDARDS FOR COMMERCIAL SUPPORT

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION STATEMENT

AcademicCME designates this live material for a maximum of 2.0 AMA PRA Category 1 Credits™. AcademicCME designates this live material for a maximum of 2.0 CNE Contact Hours (2.0 CNE Pharmacotherapeutic Contact Hours). AcademicCME designates this continuing education activity for 2.0 CPE Contact Hours (0.20 CEUs) of continuing pharmacy education credit (UAN # JA4008190-0000-25-004-L01-P). Clinicians should claim only the credit commensurate with the extent of their participation in the activity.

CE INQUIRIES/SPECIAL NEEDS

For further conference information or questions, email admin@academiccme.com.

REGISTER TODAY: [ACADEMICCME.COM/PRECMSC25](https://academiccme.com/precmsc25)

Supported by an educational grant from Bristol Myers Squibb

Provided by
academiccme



JOINT ACCREDITATION
interprofessional continuing education